Ginkgo Bioworks Holdings (DNA) Current Deferred Revenue: 2019-2025
Historic Current Deferred Revenue for Ginkgo Bioworks Holdings (DNA) over the last 4 years, with Sep 2025 value amounting to $25.2 million.
- Ginkgo Bioworks Holdings' Current Deferred Revenue rose 10.23% to $25.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.2 million, marking a year-over-year increase of 10.23%. This contributed to the annual value of $126.5 million for FY2024, which is 37.53% down from last year.
- Ginkgo Bioworks Holdings' Current Deferred Revenue amounted to $25.2 million in Q3 2025, which was down 10.79% from $28.3 million recorded in Q2 2025.
- In the past 5 years, Ginkgo Bioworks Holdings' Current Deferred Revenue ranged from a high of $222.6 million in Q4 2022 and a low of $22.9 million during Q3 2024.
- For the 3-year period, Ginkgo Bioworks Holdings' Current Deferred Revenue averaged around $74.0 million, with its median value being $33.7 million (2025).
- In the last 5 years, Ginkgo Bioworks Holdings' Current Deferred Revenue skyrocketed by 94,500.00% in 2021 and then slumped by 80.56% in 2024.
- Ginkgo Bioworks Holdings' Current Deferred Revenue (Quarterly) stood at $189.2 million in 2021, then grew by 17.65% to $222.6 million in 2022, then fell by 9.03% to $202.5 million in 2023, then slumped by 37.53% to $126.5 million in 2024, then grew by 10.23% to $25.2 million in 2025.
- Its Current Deferred Revenue was $25.2 million in Q3 2025, compared to $28.3 million in Q2 2025 and $33.7 million in Q1 2025.